Biomanufacturing capabilities
Mayo Clinic's strategy in regenerative biotherapeutics emphasizes an enhanced capability for biomanufacturing, with technology platforms supporting the development of newer therapeutics known as biotherapies. Biotherapies differ from conventional medicines that traditionally have been used to treat symptoms and manage disease. Biotherapies generally are derived from living organisms and include elements such as blood products, cells and proteins. They also often involve aspects of gene editing. Biotherapies have the potential to provide a more targeted approach to healing. The biomanufacturing capabilities in the Center for Regenerative Biotherapeutics enable healthcare teams to deliver next-generation treatments and cures for patients. The center focuses on late-stage discovery, clinical translation and manufacturing for phase 1 clinical trials.
The center's capabilities are built around a comprehensive manufacturing ecosystem that includes process and analytic development, Current Good Manufacturing Practice (cGMP) manufacturing, quality control, quality assurance and regulatory support. Its state-of-the-art development and biomanufacturing facilities allow for cutting-edge approaches to process development, manufacturing and the application of quality standards.
Focus areas
The Center for Regenerative Biotherapeutics is dedicated to developing innovative regenerative treatments and delivering them to patients. Key areas of focus include cell and gene therapies, tissue engineering, and bioprinting.
Biomanufacturing technology programs
The Center for Regenerative Biotherapeutics supports biomanufacturing technology programs in the following areas:
- Chimeric antigen receptor (CAR)-T cells.
- T-regulatory cells.
- Engineered mesenchymal stem cells (MSCs).
- Dendritic cell (DC) peptides.
- Tissue engineering and bioprinting.
- Induced pluripotent stem cell (iPSC) generation.